Inhaled Nitric Oxide in Neonates with Persistent Pulmonary Hypertension

Overview

Journal Lancet

Publisher Elsevier

Specialty General Medicine

Date 2001 Feb 24

PMID 11197402

Citations 16

Authors

W Tworetzky

J Bristow

P Moore

M M Brook

M R Segal

R C Brasch

S Hawgood

J R Fineman

Affiliations

Soon will be listed here.

Abstract

To investigate the oxygenation and haemodynamic dose response to inhaled nitric oxide in neonates with persistent pulmonary hypertension (PPHN), we gave seven neonates nitric oxide and measured directly pulmonary arterial pressure. Inhaled nitric oxide produced peak improvement in oxygenation at 5 parts per million (ppm) whereas peak improvement in the pulmonary-to-systemic arterial pressure ratio did not occur until a nitric oxide dose of 20 ppm, which suggests that an Initial dose of 20 ppm is optimum for the treatment of PPHN.

Citing Articles

Inhaled Nitric Oxide in Neonatal Pulmonary Hypertension.

Cookson M, Kinsella J Clin Perinatol. 2024; 51(1):95-111.

PMID: 38325949 PMC: 10954355. DOI: 10.1016/j.clp.2023.11.001.

Pulmonary vasodilator strategies in neonates with acute hypoxemic respiratory failure and pulmonary hypertension.

Cookson M, Abman S, Kinsella J, Mandell E Semin Fetal Neonatal Med. 2022; 27(4):101367.

PMID: 35688685 PMC: 10329862. DOI: 10.1016/j.siny.2022.101367.

Pathophysiology and Management of Persistent Pulmonary Hypertension of the Newborn.

Singh Y, Lakshminrusimha S Clin Perinatol. 2021; 48(3):595-618.

PMID: 34353582 PMC: 8351908. DOI: 10.1016/j.clp.2021.05.009.

When to say no to inhaled nitric oxide in neonates?.

Chandrasekharan P, Lakshminrusimha S, Abman S Semin Fetal Neonatal Med. 2021; 26(2):101200.

PMID: 33509680 PMC: 11867762. DOI: 10.1016/j.siny.2021.101200.

The CoDiNOS trial protocol: an international randomised controlled trial of intravenous sildenafil versus inhaled nitric oxide for the treatment of pulmonary hypertension in neonates with congenital diaphragmatic hernia.

Otter S, Schaible T, Greenough A, van Heijst A, Patel N, Allegaert K BMJ Open. 2019; 9(11):e032122.

PMID: 31694851 PMC: 6858099. DOI: 10.1136/bmjopen-2019-032122.